Alto Neuroscience (ANRO) Free Cash Flow (2023 - 2026)
Alto Neuroscience (ANRO) reported Free Cash Flow of -$28.0 million for Q1 2026, down 69.07% on a YoY basis from -$90.6 million in Q1 2025, and down 143.42% sequentially from -$11.5 million in Q4 2025.
Alto Neuroscience (ANRO) Free Cash Flow (2023 - 2026) Analysis & Trends
Alto Neuroscience (ANRO) has 4 years of Free Cash Flow data on file, last reported at -$28.0 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 69.07% year-over-year to -$28.0 million; the trailing twelve-month figure through Mar 2026 stood at -$63.2 million (down 19.79% YoY), and the FY2025 full-year result was -$51.8 million, down 9.21% from the prior year.
- Free Cash Flow fell to -$28.0 million in Q1 2026, from -$11.5 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$6.7 million in Q2 2023 to a low of -$28.0 million in Q1 2026.
- A 4-year average of -$12.4 million and a median of -$11.5 million in 2025 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow plunged 79.34% in 2024 and gained 11.4% in 2025, its largest moves.
- Tracing ANRO's Free Cash Flow over 4 years: stood at -$12.0 million in 2023, then retreated by 8.3% to -$13.0 million in 2024, then increased by 11.34% to -$11.5 million in 2025, then slumped by 143.42% to -$28.0 million in 2026.
- Business Quant data shows ANRO's Free Cash Flow at -$28.0 million in Q1 2026, -$11.5 million in Q4 2025, and -$9.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -354.95 Mn |
| 10 | Alto Neuroscience | 869.36 Mn | 869.36 Mn | - | -28.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.03 Mn |
| Mar 31, 2026 | -28.03 Mn |
| Dec 31, 2025 | -11.52 Mn |
| Dec 31, 2025 | -11.52 Mn |
| Sep 30, 2025 | -9.92 Mn |
| Sep 30, 2025 | -9.92 Mn |
| Jun 30, 2025 | -13.78 Mn |
| Jun 30, 2025 | -13.78 Mn |
| Mar 31, 2025 | -16.58 Mn |
| Mar 31, 2025 | -16.58 Mn |
| Dec 31, 2024 | -12.99 Mn |
| Dec 31, 2024 | -12.99 Mn |
| Sep 30, 2024 | -11.19 Mn |
| Sep 30, 2024 | -11.19 Mn |
| Jun 30, 2024 | -12.03 Mn |
| Jun 30, 2024 | -12.03 Mn |
| Mar 31, 2024 | -11.21 Mn |
| Mar 31, 2024 | -11.21 Mn |
| Dec 31, 2023 | -11.99 Mn |
| Dec 31, 2023 | -11.99 Mn |